Tags

Type your tag names separated by a space and hit enter

Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Jpn J Clin Oncol. 2019 Jul 01; 49(7):671-675.JJ

Abstract

BACKGROUND

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients who have good performance status (PS). However, the efficacy and safety of osimertinib for patients with poor PS is unknown.

METHODS

We retrospectively evaluated the efficacy and safety of osimertinib in patients with EGFR T790M mutation-positive NSCLC who had Eastern Cooperative Oncology Group PS scores of 2-4 and who were administered 80 mg of osimertinib once daily between March 2016 and February 2017.

RESULTS

Thirty patients (8 men and 22 women) with EGFR T790M mutation-positive NSCLC were evaluated; their median age was 66 years (range: 39-89 years). Twenty-four and six patients had PS scores of 2 and 3, respectively; none had a PS score of 4. All patients had previously been treated with first- or second-generation EGFR-TKIs. T790M was detected in the tumor samples of 23 patients, the blood samples of two patients, and both the tumor and blood samples of five patients. The overall response rate was 53% (95% confidence interval: 36-70%), and the PS score improvement rate was 63%. The median progression-free survival was 8.2 months (95% confidence interval: 4.3-13.2 months), while the median overall survival time was not reached. No patient required treatment cessation owing to adverse events, and no treatment-related deaths occurred.

CONCLUSIONS

Osimertinib therapy demonstrates promising efficacy and acceptable safety in patients with EGFR T790M mutation-positive NSCLC who have poor PS.

Authors+Show Affiliations

Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.Internal Medicine III, Wakayama Medical University, Wakayama, Japan.Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan.Division of Pulmonary Medicine, Minami Kyushu National Hospital, Kagoshima, Japan.Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Japan.Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.Internal Medicine III, Wakayama Medical University, Wakayama, Japan.Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.No affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

30920616

Citation

Nakashima, Kazuhisa, et al. "Osimertinib for Patients With EGFR T790M Mutation-positive Non-small-cell Lung Cancer and a Poor Performance Status." Japanese Journal of Clinical Oncology, vol. 49, no. 7, 2019, pp. 671-675.
Nakashima K, Kimura M, Akamatsu H, et al. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Jpn J Clin Oncol. 2019;49(7):671-675.
Nakashima, K., Kimura, M., Akamatsu, H., Daga, H., Imai, H., Taira, T., Ko, R., Hisamatsu, Y., Nishino, K., Sugimoto, T., Miyashita, Y., & Takahashi, T. (2019). Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Japanese Journal of Clinical Oncology, 49(7), 671-675. https://doi.org/10.1093/jjco/hyz041
Nakashima K, et al. Osimertinib for Patients With EGFR T790M Mutation-positive Non-small-cell Lung Cancer and a Poor Performance Status. Jpn J Clin Oncol. 2019 Jul 1;49(7):671-675. PubMed PMID: 30920616.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. AU - Nakashima,Kazuhisa, AU - Kimura,Madoka, AU - Akamatsu,Hiroaki, AU - Daga,Haruko, AU - Imai,Hisao, AU - Taira,Tetsuhiko, AU - Ko,Ryo, AU - Hisamatsu,Yasushi, AU - Nishino,Kazumi, AU - Sugimoto,Takeya, AU - Miyashita,Yosuke, AU - Takahashi,Toshiaki, AU - ,, PY - 2019/01/24/received PY - 2019/02/22/revised PY - 2019/03/19/accepted PY - 2019/3/29/pubmed PY - 2019/10/31/medline PY - 2019/3/29/entrez KW - EGFR T790M mutation-positive KW - non–small-cell lung cancer KW - osimertinib KW - poor performance status SP - 671 EP - 675 JF - Japanese journal of clinical oncology JO - Jpn. J. Clin. Oncol. VL - 49 IS - 7 N2 - BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients who have good performance status (PS). However, the efficacy and safety of osimertinib for patients with poor PS is unknown. METHODS: We retrospectively evaluated the efficacy and safety of osimertinib in patients with EGFR T790M mutation-positive NSCLC who had Eastern Cooperative Oncology Group PS scores of 2-4 and who were administered 80 mg of osimertinib once daily between March 2016 and February 2017. RESULTS: Thirty patients (8 men and 22 women) with EGFR T790M mutation-positive NSCLC were evaluated; their median age was 66 years (range: 39-89 years). Twenty-four and six patients had PS scores of 2 and 3, respectively; none had a PS score of 4. All patients had previously been treated with first- or second-generation EGFR-TKIs. T790M was detected in the tumor samples of 23 patients, the blood samples of two patients, and both the tumor and blood samples of five patients. The overall response rate was 53% (95% confidence interval: 36-70%), and the PS score improvement rate was 63%. The median progression-free survival was 8.2 months (95% confidence interval: 4.3-13.2 months), while the median overall survival time was not reached. No patient required treatment cessation owing to adverse events, and no treatment-related deaths occurred. CONCLUSIONS: Osimertinib therapy demonstrates promising efficacy and acceptable safety in patients with EGFR T790M mutation-positive NSCLC who have poor PS. SN - 1465-3621 UR - https://www.unboundmedicine.com/medline/citation/30920616/Osimertinib_for_patients_with_EGFR_T790M_mutation_positive_non_small_cell_lung_cancer_and_a_poor_performance_status_ L2 - https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjco/hyz041 DB - PRIME DP - Unbound Medicine ER -